1-3 of 3
Martin Jädersten
Close
Sort by
Journal Articles

Venetoclax–based low intensity therapy in molecular failure of NPM1 -mutated AML

Clinical Trials & Observations
Carlos Jimenez-Chillon, Jad Othman, David Taussig, Carlos Jimenez-Vicente, Alexandra Martinez-Roca, Ing Soo Tiong, Manish Jain, James Aries, Seda Cakmak, Steven Knapper, Daniel Tuyet Kristensen, Vidhya Murthy, Joy Zacharoula Galani, Charlotte Kallmeyer, Loretta Ngu, David Veale, Simon Bolam, Nina Orfali, Anne Parker, Cara Manson, Jane Parker, Thomas Erblich, Deborah Richardson, Katya Mokretar, Nicola Potter, Ulrik Malthe Overgaard, Anne Stidsholt Roug, Andrew H. Wei, Jordi Esteve, Martin Jädersten, Nigel Russell, Richard Dillon
Journal: Blood Advances
Blood Adv (2024) 8 (2): 343–352.
https://doi.org/10.1182/bloodadvances.2023011106
Published: 2024
Includes: Supplemental data
Journal Articles

The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1 -mutated MDS-RS

Isabel Juliana F. Hofman, Teresa Mortera-Blanco, Pedro Luis Moura, Johanna Vestlund, Sigita Venckute Larsson, Edda M. Elvarsdottir, Gunilla Walldin, Magnus Tobiasson, Birgitta Sander, Marios Dimitriou, Sten-Eirik W. Jacobsen, Petter S. Woll, Martin Jädersten, Eva Hellström-Lindberg
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4705–4709.
https://doi.org/10.1182/bloodadvances.2022007858
Published: 2022
Includes: Supplemental data
Journal Articles

The prognostic impact of FLT3 -ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Clinical Trials & Observations
Gunnar Juliusson, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Lars Möllgård, Lovisa Wennström, Petar Antunovic, Jörg Cammenga, Fryderyk Lorenz, Emma Ölander, Vladimir Lj Lazarevic, Martin Höglund
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1094–1101.
https://doi.org/10.1182/bloodadvances.2019001335
Published: 2020
Includes: Supplemental data